Cabozantinib eradicates advanced murine prostate cancer by activating anti-tumor innate immunity

Several kinase inhibitors that target aberrant signaling pathways in tumor cells have been deployed in cancer therapy. However, their impact on the tumor immune microenvironment remains poorly understood. The tyrosine kinase inhibitor cabozantinib showed striking responses in cancer clinical trial p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Patnaik, Akash, Swanson, Kenneth D., Csizmadia, Eva, Solanki, Aniruddh, Landon-Brace, Natalie, Gehring, Marina P., Helenius, Katja, Olson, Brian M., Pyzer, Athalia R., Wang, Lily C., Elemento, Olivier, Novak, Jesse, Thornley, Thomas B., Asara, John M., Montaser, Laleh, Timmons, Joshua J., Morgan, Todd M., Wang, Yugang, Levantini, Elena, Clohessy, John G., Kelly, Kathleen, Pandolfi, Pier Paolo, Rosenblatt, Jacalyn M., Avigan, David E., Ye, Huihui, Karp, Jeffrey M., Signoretti, Sabina, Balk, Steven P., Cantley, Lewis C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5501767/
https://ncbi.nlm.nih.gov/pubmed/28274958
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0778
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados